ErbB pathway dysregulation has been proposed to play a pathogenic role in ALS, especially ErbB4, a member of the epidermal growth factor (EGF) subfamily of receptor tyrosine kinases (RTKs) (Casanovas et al., 2017). Here, EGF is linked to amyotrophic lateral sclerosis.